RU2018108050A - 5-BROM-2,6-DI- (1H-PYRAZOL-1-IL) PYRIMIDIN-4-AMINE FOR USE IN CANCER TREATMENT - Google Patents
5-BROM-2,6-DI- (1H-PYRAZOL-1-IL) PYRIMIDIN-4-AMINE FOR USE IN CANCER TREATMENT Download PDFInfo
- Publication number
- RU2018108050A RU2018108050A RU2018108050A RU2018108050A RU2018108050A RU 2018108050 A RU2018108050 A RU 2018108050A RU 2018108050 A RU2018108050 A RU 2018108050A RU 2018108050 A RU2018108050 A RU 2018108050A RU 2018108050 A RU2018108050 A RU 2018108050A
- Authority
- RU
- Russia
- Prior art keywords
- seq
- amino acid
- acid sequence
- compound
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (33)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382425 | 2015-08-11 | ||
EP15382425.5 | 2015-08-11 | ||
US201662335984P | 2016-05-13 | 2016-05-13 | |
US62/335,984 | 2016-05-13 | ||
PCT/IB2016/054834 WO2017025918A1 (en) | 2015-08-11 | 2016-08-10 | 5-bromo-2,6-di-(lh-pyrazol-l-yl)pyrimidin-4-amine for use in the treatment of cancer |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2021106602A Division RU2021106602A (en) | 2015-08-11 | 2016-08-10 | 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN CANCER TREATMENT |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018108050A true RU2018108050A (en) | 2019-09-13 |
RU2018108050A3 RU2018108050A3 (en) | 2020-02-17 |
RU2745560C2 RU2745560C2 (en) | 2021-03-29 |
Family
ID=65563017
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018108050A RU2745560C2 (en) | 2015-08-11 | 2016-08-10 | 5-bromo-2,6-di - (1h-pyrazol-1-yl)pyrimidine-4-amine for use in cancer treatment |
Country Status (13)
Country | Link |
---|---|
JP (1) | JP6964113B2 (en) |
KR (1) | KR102226100B1 (en) |
CL (1) | CL2018000349A1 (en) |
DK (1) | DK3334431T3 (en) |
ES (1) | ES2761910T3 (en) |
HK (1) | HK1249409B (en) |
HR (1) | HRP20192192T1 (en) |
HU (1) | HUE046646T2 (en) |
IL (1) | IL257350A (en) |
LT (1) | LT3334431T (en) |
PT (1) | PT3334431T (en) |
RU (1) | RU2745560C2 (en) |
ZA (1) | ZA201800792B (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2365960B1 (en) * | 2010-03-31 | 2012-06-04 | Palobiofarma, S.L | NEW ANTAGONISTS OF ADENOSINE RECEPTORS. |
-
2016
- 2016-08-10 PT PT167663848T patent/PT3334431T/en unknown
- 2016-08-10 ES ES16766384T patent/ES2761910T3/en active Active
- 2016-08-10 KR KR1020207013977A patent/KR102226100B1/en active IP Right Grant
- 2016-08-10 HU HUE16766384A patent/HUE046646T2/en unknown
- 2016-08-10 RU RU2018108050A patent/RU2745560C2/en active
- 2016-08-10 DK DK16766384.8T patent/DK3334431T3/en active
- 2016-08-10 LT LTEP16766384.8T patent/LT3334431T/en unknown
-
2018
- 2018-02-04 IL IL257350A patent/IL257350A/en active IP Right Grant
- 2018-02-07 CL CL2018000349A patent/CL2018000349A1/en unknown
- 2018-02-07 ZA ZA2018/00792A patent/ZA201800792B/en unknown
- 2018-06-22 HK HK18108031.4A patent/HK1249409B/en unknown
-
2019
- 2019-06-18 JP JP2019112726A patent/JP6964113B2/en active Active
- 2019-12-04 HR HRP20192192TT patent/HRP20192192T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
HUE046646T2 (en) | 2020-03-30 |
JP2019218346A (en) | 2019-12-26 |
ZA201800792B (en) | 2019-06-26 |
JP6964113B2 (en) | 2021-11-10 |
RU2745560C2 (en) | 2021-03-29 |
HRP20192192T1 (en) | 2020-03-06 |
HK1249409B (en) | 2020-05-08 |
KR102226100B1 (en) | 2021-03-10 |
IL257350A (en) | 2018-03-29 |
LT3334431T (en) | 2019-12-27 |
KR20200057790A (en) | 2020-05-26 |
ES2761910T3 (en) | 2020-05-21 |
RU2018108050A3 (en) | 2020-02-17 |
CL2018000349A1 (en) | 2018-09-07 |
PT3334431T (en) | 2020-01-06 |
DK3334431T3 (en) | 2020-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20191824T1 (en) | Agonistic tnf receptor binding agents | |
CO2018010919A2 (en) | Novel b7-h3 binding molecules, antibody-drug conjugates thereof and methods of use thereof | |
JP2019503349A5 (en) | ||
JP2020023523A5 (en) | ||
JP2018508462A5 (en) | ||
JP2017535257A5 (en) | ||
RU2017108173A (en) | COMBINED THERAPY BASED ON ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES TO HUMAN PD-L1 | |
RU2017104813A (en) | MOLECULES SPECIFICALLY TO CD45 AND CD79 | |
RU2018105846A (en) | COMBINATION OF PD-1 ANTAGONIST WITH EGFR INHIBITOR | |
JP2018501197A5 (en) | ||
AR079903A1 (en) | FORMULATION OF ANTIBODY AND THERAPEUTIC REGIMES. PHARMACEUTICAL PACKAGING. KIT | |
RU2018106876A (en) | A NEW COMBINATION FOR APPLICATION IN TREATMENT OF MALIGNANT NOVEL EDUCATION | |
FI3484915T3 (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
PE20231958A1 (en) | BINDING MOLECULES TO PD-1 AND METHODS OF USE THEREOF | |
RU2014109039A (en) | BSPECIFIC ANTIGEN BINDING MOLECULES | |
JP2017536414A5 (en) | ||
RU2016106577A (en) | SPECIFICALLY BINDING ANTIBODY SITES EGFRvIII | |
RU2010145177A (en) | LIVER CANCER TREATMENT | |
EA201490020A1 (en) | SOLUBLE PROTEINS FOR USE AS THERAPEUTIC TOOLS | |
RU2018102606A (en) | MOLECULES RELATING TO PSL PSEUDOMONAS AND WAYS OF THEIR APPLICATION | |
RU2014120154A (en) | STABLE ANTIBODIES COMBINING WITH MULTIPLE ANTIGENS | |
MX2014008101A (en) | Dual variable domain immunoglobulins against il-13 and/or il-17. | |
PE20090518A1 (en) | ANTIGEN-BINDING PROTEINS THAT BIND THE INTERLEUKIN-18 (IL-18) RECEPTOR | |
RU2016129894A (en) | COVALENTLY RELATED HELICAR-ANTIBODY CONJUGATES AGAINST HELICAR AND THEIR APPLICATION | |
RU2018125603A (en) | COMBINATION OF C-MET INHIBITOR WITH ANTIBODY MOLECULE TO PD-1 AND ITS APPLICATIONS |